Presented in part at the 57th Annual Meeting of the American Association of Blood Banks in Baltimore, MD, October 25, 2004.
Article first published online: 19 JAN 2006
Copyright © 2006 Wiley-Liss, Inc.
Journal of Clinical Apheresis
Volume 21, Issue 3, pages 158–164, October 2006
How to Cite
Liumbruno, G. M., Centoni, P. E., Molfettini, P., Ceretelli, S., Ceccarini, M., Bachini, L., Pomponi, A., Bagnoni, G., Vitolo, M., Eberle, O., Biondi, A. and Sodini, M. L. (2006), Lymphocytapheresis in the treatment of psoriasis vulgaris . J. Clin. Apheresis, 21: 158–164. doi: 10.1002/jca.20079
Abbreviations used: BSA = body surface area; DCs = dendritic cells; GCAP = granulocyte and monocyte adsorption apheresis; LCA = lymphocytapheresis; PASI = psoriasis area and severity index; PP = pustular psoriasis; PRBV = percentage of reduction from baseline value; PV = psoriasis vulgaris; QoL = quality of life; TBV = total blood volume; Th1 = type 1.
- Issue published online: 27 OCT 2006
- Article first published online: 19 JAN 2006
- Manuscript Accepted: 3 OCT 2005
- Manuscript Received: 1 JUN 2005
- lymphocyte depletion;
- autoimmune skin disease;
Psoriasis is a common autoimmune chronic inflammatory skin disease that affects approximately 2% of the world's population; fundamental for its immunopathogenic mechanism is secretion of type 1 (Th1) cytokines by T cells and their activation. Since cytapheresis has been widely applied to autoimmune disorders, emphasizing the recently reported results of granulocyte and monocyte adsorption apheresis in psoriasis, a small series of psoriasis vulgaris (PV) patients underwent lymphocytapheresis (LCA) with the aim to remove lymphocytes. Five patients were submitted to weekly LCA. The severity of the disease had been evaluated through psoriasis area and severity index (PASI) score before LCA and one week after the last apheresis. PASI score before: patient A: 66; patient B: 33; patient C: 50; patient D: 56; patient E: 29. All the patients showed improvement of skin lesions. PASI score after LCA: patient A: 24; patient B: 8; patient C: 5; patient D: 36; patient E: 2.1. No side effects linked to apheresis were reported. LCA seems to produce interesting results in PV, and PASI improvement related to apheresis is clinically significant. Further studies to address its mechanism of action and potential long-term side effects are needed. It could become a valuable therapeutic alternative or a complementary tool, which might even be used to reduce the dosages of conventional pharmacological therapies adopted for this chronic disease. J. Clin. Apheresis 2006. © 2006 Wiley-Liss, Inc.